Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBITDA: 2017-2024

Historic EBITDA for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to -$43.4 million.

  • Kiniksa Pharmaceuticals International's EBITDA rose 245.45% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year increase of 493.10%. This contributed to the annual value of -$43.4 million for FY2024, which is 408.71% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its EBITDA stood at -$43.4 million for FY2024, which was down 408.71% from $14.0 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's EBITDA registered a high of $183.5 million during FY2022, and its lowest value of -$161.4 million during FY2020.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median EBITDA value was $14.0 million (recorded in 2023), while the average stood at $51.4 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's EBITDA surged by 216.15% in 2022 and then crashed by 408.71% in 2024.
  • Yearly analysis of 5 years shows Kiniksa Pharmaceuticals International's EBITDA stood at -$161.4 million in 2020, then grew by 2.16% to -$158.0 million in 2021, then soared by 216.15% to $183.5 million in 2022, then slumped by 92.34% to $14.0 million in 2023, then crashed by 408.71% to -$43.4 million in 2024.